Zhitong Financial APP learned that Sihuan Pharmaceuticals (00460) continued to put volume up, and its shares rose about 5 per cent against the market at the beginning of the day. As of press time, Sihuan Pharmaceutical rose 4.88% to HK $1.72, with a turnover of HK $129 million.

Sihuan Pharmaceutical (00460.HK) announced at noon on November 25th that the application of Xuanzhu Biology of the Group to conduct phase III clinical trials of class 1 innovative drug pyrrosinil (Birociclib,XZP-3287CDK4/6 (inhibitor of cell cycle dependent kinase 4 and 6) ("Pirosini") has been formally approved. The combination of pyrrosinil and aromatase inhibitors is used in locally advanced or metastatic breast cancer with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). In addition, in August this year, the combination of Pirosinil and flurvist was also approved for phase III clinical trials.

Sihuan Medicine said that at present, Xuanzhu Biology has more than 25 new drugs under development, and more than 10 new drugs are in different clinical stages.